|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Heidelberger C, Chaudhuri NK, Danneberg P,
Mooren D, Griesbach L, Duschinsky R, Schnitzer RJ, Pleven E and
Scheiner J: Fluorinated pyrimidines, a new class of
tumour-inhibitory compounds. Nature. 179:663–666. 1957. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Malet-Martino M and Martino R: Clinical
studies of three oral prodrugs of 5-fluorouracil (capecitabine,
UFT, S-1): A review. Oncologist. 7:288–323. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sebag-Montefiore D, Glynne-Jones R, Falk
S, Meadows HM and Maughan T: A phase I/II study of oxaliplatin when
added to 5-fluorouracil and leucovorin and pelvic radiation in
locally advanced rectal cancer: A Colorectal Clinical Oncology
Group (CCOG) study. Br J Cancer. 93:993–998. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tsuruta M, Nishibori H, Hasegawa H, Ishii
Y, Endo T, Kubota T, Kitajima M and Kitagawa Y: Heat shock protein
27, a novel regulator of 5-fluorouracil resistance in colon cancer.
Oncol Rep. 20:1165–1172. 2008.PubMed/NCBI
|
|
6
|
Valeri N, Gasparini P, Braconi C, Paone A,
Lovat F, Fabbri M, Sumani KM, Alder H, Amadori D, Patel T, et al:
MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating
human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci USA. 107:pp.
21098–21103. 2010; View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Longley DB, Harkin DP and Johnston PG:
5-Fluorouracil: Mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Su X, Malouf GG, Chen Y, Zhang J, Yao H,
Valero V, Weinstein JN, Spano JP, Meric-Bernstam F, Khayat D, et
al: Comprehensive analysis of long non-coding RNAs in human breast
cancer clinical subtypes. Oncotarget. 5:9864–9876. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cheng N, Li X, Zhao C, Ren S, Chen X, Cai
W, Zhao M, Zhang Y, Li J, Wang Q, et al: Microarray expression
profile of long non-coding RNAs in EGFR-TKIs resistance of human
non-small cell lung cancer. Oncol Rep. 33:833–839. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Luo J, Xu L, Jiang Y, Zhuo D, Zhang S, Wu
L, Xu H and Huang Y: Expression profile of long non-coding RNAs in
colorectal cancer: A microarray analysis. Oncol Rep. 35:2035–2044.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tano K and Akimitsu N: Long non-coding
RNAs in cancer progression. Front Genet. 3:2192012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Malek E, Jagannathan S and Driscoll JJ:
Correlation of long non-coding RNA expression with metastasis, drug
resistance and clinical outcome in cancer. Oncotarget. 5:8027–8038.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Q, Cheng N, Li X, Pan H, Li C, Ren S,
Su C, Cai W, Zhao C, Zhang L, et al: Correlation of long non-coding
RNA H19 expression with cisplatin-resistance and clinical outcome
in lung adenocarcinoma. Oncotarget. 8:2558–2567. 2017.PubMed/NCBI
|
|
14
|
Wang Y, Wu K, Yang Z, Zhao Q and Fan D, Xu
P, Nie Y and Fan D: Multidrug-resistance related long non-coding
RNA expression profile analysis of gastric cancer. PLoS One.
10:e01354612015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pan J, Li X, Wu W, Xue M, Hou H, Zhai W
and Chen W: Long non-coding RNA UCA1 promotes cisplatin/gemcitabine
resistance through CREB modulating miR-196a-5p in bladder cancer
cells. Cancer Lett. 382:64–76. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lan WG, Xu DH, Xu C, Ding CL, Ning FL,
Zhou YL, Ma LB, Liu CM and Han X: Silencing of long non-coding RNA
ANRIL inhibits the development of multidrug resistance in gastric
cancer cells. Oncol Rep. 36:263–270. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu E, Liu Z, Zhou Y, Mi R and Wang D:
Overexpression of long non-coding RNA PVT1 in ovarian cancer cells
promotes cisplatin resistance by regulating apoptotic pathways. Int
J Clin Exp Med. 8:20565–20572. 2015.PubMed/NCBI
|
|
18
|
Wang F, Zhou J, Xie X, Hu J, Chen L, Hu Q,
Guo H and Yu C: Involvement of SRPK1 in cisplatin resistance
related to long non-coding RNA UCA1 in human ovarian cancer cells.
Neoplasma. 62:432–438. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang L, Qiu M, Xu Y, Wang J, Zheng Y, Li
M, Xu L and Yin R: Upregulation of long non-coding RNA PRNCR1 in
colorectal cancer promotes cell proliferation and cell cycle
progression. Oncol Rep. 35:318–324. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu C, Yang M, Tian J, Wang X and Li Z:
MALAT-1: A long non-coding RNA and its important 3′ end functional
motif in colorectal cancer metastasis. Int J Oncol. 39:169–175.
2011.PubMed/NCBI
|
|
21
|
Kogo R, Shimamura T, Mimori K, Kawahara K,
Imoto S, Sudo T, Tanaka F, Shibata K, Suzuki A, Komune S, et al:
Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin
modification and is associated with poor prognosis in colorectal
cancers. Cancer Res. 71:6320–6326. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Niu H, Hu Z, Liu H, Hu G, Yang B, Wu S and
Li F: Long non-coding RNA AK027294 involves in the process of
proliferation, migration, and apoptosis of colorectal cancer cells.
Tumour Biol. 37:10097–10105. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xiong W, Jiang YX, Ai YQ, Liu S, Wu XR,
Cui JG, Qin JY, Liu Y, Xia YX, Ju YH, et al: Microarray analysis of
long non-coding RNA expression profile associated with
5-fluorouracil-based chemoradiation resistance in colorectal cancer
cells. Asian Pac J Cancer Prev. 16:3395–3402. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu X, Cheng Y, Chen X, Yang J, Xu L and
Zhang C: MicroRNA-31 regulated by the extracellular regulated
kinase is involved in vascular smooth muscle cell growth via large
tumor suppressor homolog 2. J Biol Chem. 286:42371–42380. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang CJ, Stratmann J, Zhou ZG and Sun XF:
Suppression of microRNA-31 increases sensitivity to 5-FU at an
early stage, and affects cell migration and invasion in HCT-116
colon cancer cells. BMC Cancer. 10:6162010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dong Z, Zhong Z, Yang L, Wang S and Gong
Z: MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small
cell lung cancer cells by regulating the drug transporter ABCB9.
Cancer Lett. 343:249–257. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Miyashita T, Krajewski S, Krajewska M,
Wang HG, Lin HK, Liebermann DA, Hoffman B and Reed JC: Tumor
suppressor p53 is a regulator of bcl-2 and bax gene expression in
vitro and in vivo. Oncogene. 9:1799–1805. 1994.PubMed/NCBI
|
|
28
|
Gong C, Popp MW and Maquat LE: Biochemical
analysis of long non-coding RNA-containing ribonucleoprotein
complexes. Methods. 58:88–93. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hou P, Zhao Y, Li Z, Yao R, Ma M, Gao Y,
Zhao L, Zhang Y, Huang B and Lu J: LincRNA-ROR induces
epithelial-to-mesenchymal transition and contributes to breast
cancer tumorigenesis and metastasis. Cell Death Dis. 5:e12872014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hwang IT, Chung YM, Kim JJ, Chung JS, Kim
BS, Kim HJ, Kim JS and Yoo YD: Drug resistance to 5-FU linked to
reactive oxygen species modulator 1. Biochem Biophys Res Commun.
359:304–310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hwang PM, Bunz F, Yu J, Rago C, Chan TA,
Murphy MP, Kelso GF, Smith RA, Kinzler KW and Vogelstein B:
Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced
apoptosis in colorectal cancer cells. Nat Med. 7:1111–1117. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Borralho PM, Kren BT, Castro RE, da Silva
IB, Steer CJ and Rodrigues CM: MicroRNA-143 reduces viability and
increases sensitivity to 5-fluorouracil in HCT116 human colorectal
cancer cells. FEBS J. 276:6689–6700. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Choi S and Ku JL: Resistance of colorectal
cancer cells to radiation and 5-FU is associated with MELK
expression. Biochem Biophys Res Commun. 412:207–213. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Spitzner M, Emons G, Kramer F, Gaedcke J,
Rave-Fränk M, Scharf JG, Burfeind P, Becker H, Beissbarth T,
Ghadimi BM, et al: A gene expression signature for
chemoradiosensitivity of colorectal cancer cells. Int J Radiat
Oncol Biol Phys. 78:1184–1192. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fu J, Tang W, Du P, Wang G, Chen W, Li J,
Zhu Y, Gao J and Cui L: Identifying microRNA-mRNA regulatory
network in colorectal cancer by a combination of expression profile
and bioinformatics analysis. BMC Syst Biol. 6:682012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Diederichs S: Long non-coding RNA &
cancer. Proceedings of the 37th World Congress of the International
Union of Physiological Sciences. Birmingham, UK. 2013;
|
|
37
|
Pickard MR and Williams GT: Regulation of
apoptosis by long non-coding RNA GAS5 in breast cancer cells:
Implications for chemotherapy. Breast Cancer Res Treat.
145:359–370. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xu XM, Qian JC, Deng ZL, Cai Z, Tang T,
Wang P, Zhang KH and Cai JP: Expression of miR-21, miR-31, miR-96
and miR-135b is correlated with the clinical parameters of
colorectal cancer. Oncol Lett. 4:339–345. 2012.PubMed/NCBI
|
|
39
|
Cesana M, Cacchiarelli D, Legnini I,
Santini T, Sthandier O, Chinappi M, Tramontano A and Bozzoni I: A
long noncoding RNA controls muscle differentiation by functioning
as a competing endogenous RNA. Cell. 147:358–369. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Memczak S, Jens M, Elefsinioti A, Torti F,
Krueger J, Rybak A, Maier L, Mackowiak SD, Gregersen LH, Munschauer
M, et al: Circular RNAs are a large class of animal RNAs with
regulatory potency. Nature. 495:333–338. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Deng L, Yang SB, Xu FF and Zhang JH: Long
noncoding RNA CCAT1 promotes hepatocellular carcinoma progression
by functioning as let-7 sponge. J Exp Clin Cancer Res. 34:182015.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhou X, Ye F, Yin C, Zhuang Y, Yue G and
Zhang G: The Interaction between miR-141 and lncRNA-H19 in
regulating cell proliferation and migration in gastric cancer. Cell
Physiol Biochem. 36:1440–1452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cai H, Yao J, An Y, Chen X, Chen W, Wu D,
Luo B, Yang Y, Jiang Y, Sun D, et al: LncRNA HOTAIR acts a
competing endogenous RNA to control the expression of notch3 via
sponging miR-613 in pancreatic cancer. Oncotarget. 8:32905–32917.
2017.PubMed/NCBI
|
|
44
|
Yu F, Lu Z, Cai J, Huang K, Chen B, Li G,
Dong P and Zheng J: MALAT1 functions as a competing endogenous RNA
to mediate Rac1 expression by sequestering miR-101b in liver
fibrosis. Cell Cycle. 14:3885–3896. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wang SH, Zhang WJ, Wu XC, Weng MZ, Zhang
MD, Cai Q, Zhou D, Wang JD and Quan ZW: The lncRNA MALAT1 functions
as a competing endogenous RNA to regulate MCL-1 expression by
sponging miR-363-3p in gallbladder cancer. J Cell Mol Med.
20:2299–2308. 2016. View Article : Google Scholar : PubMed/NCBI
|
